Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables JW SH NY SC 2.1K 14th Jan, 2026
Possibly higher DOC GPS import quota for 2026F
Rising risk of broiler oversupply
Higher input costs add exert pressure on poultry feed margins
Downside risks are becoming more apparent
| Bear | Base | Bull | Remarks | |
| Total productive days | 20 days x 12 months: 240 days | 104 weekends, 25 national holiday and annual leave | ||
| Target mn recipients/day | 24.9 | 41.5 | 82.9 | Bull: Govt target of 82.9 recipient. Base: 50% of target, Bear: 30% of target |
| # of cut for a single broiler | 10 pieces, twice a week | 2 breast, 2 thighs, 2 drumsticks, 2 wings, 2 tenderloins, twice a week | ||
| Total broiler needed (mn unit) | 239 | 398 | 796 | twice a week x productive days × recipients × # of cut |
| Avg broiler mass (kg) | 1.62 | Avg of a 30 days-old broiler | ||
| Additional broiler from MBG (mn tons) | 387 | 645 | 1,289 | Broiler needed × avg broiler mass |
| 2024 annual supply (mn tons) | 3,840 | Latest print | ||
| Addition from MBG to existing supply | 10.1% | 16.8% | 33.6% | |
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
Jody Wijaya (jody.wijaya@verdhana.id),
Sandy Ham (sandy.ham@verdhana.id),
Nayla Yasmin (nayla.yasmin@verdhana.id), and
Samuel Christian (samuel.christian@verdhana.id)
saya
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Based on our survey of distributors and wholesalers, MYOR's domestic sales may have grown
As mentioned in our previous reports, Indonesia local FMCG companies have
Our analysis of FMCG and retail sales data of companies we track across Indonesia suggests that Sulawesi,
AMRT has consistently outperformed its FMCG peers in terms of sales growth over the past decade
Indonesia is a young nation (110mn population are below 40yrs, based on BPS) as well as social media-savvy (th